AstraZeneca’s Farxiga DELIVERs With Fresh Heart Failure Data

In competition with Boehringer And Lilly’s Jardiance

AstraZeneca's SGLT2 inhibitor Farxiga could soon get approval as an option for all heart failure patients following the success of the large Phase III DELIVER trial in people with preserved ejection fraction.

heart failure picture
• Source: Alamy

The battle to be the best-selling SGLT2 inhibitor continues to heat up after AstraZeneca PLC revealed data demonstrating that Farxiga, like Boehringer Ingelheim GmbH/Eli Lilly and Company's rival therapy Jardiance, is an effective treatment for heart failure regardless of ejection fraction.

The UK major has presented topline results from the DELIVER Phase III trial which showed that Farxiga/Forxiga (dapagliflozin) reduced the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Cardiovascular

More from Therapeutic Category